Guerra-Ávila, P.L.; Guzmán, T.J.; Domínguez-Rosales, J.A.; García-López, P.M.; Cervantes-Garduño, A.B.; Wink, M.; Gurrola-Díaz, C.M.
Combined Gamma Conglutin and Lupanine Treatment Exhibits In Vivo an Enhanced Antidiabetic Effect by Modulating the Liver Gene Expression Profile. Pharmaceuticals 2023, 16, 117.
https://doi.org/10.3390/ph16010117
AMA Style
Guerra-Ávila PL, Guzmán TJ, Domínguez-Rosales JA, García-López PM, Cervantes-Garduño AB, Wink M, Gurrola-Díaz CM.
Combined Gamma Conglutin and Lupanine Treatment Exhibits In Vivo an Enhanced Antidiabetic Effect by Modulating the Liver Gene Expression Profile. Pharmaceuticals. 2023; 16(1):117.
https://doi.org/10.3390/ph16010117
Chicago/Turabian Style
Guerra-Ávila, Paloma Lucía, Tereso J. Guzmán, José Alfredo Domínguez-Rosales, Pedro Macedonio García-López, Alejandra Beatriz Cervantes-Garduño, Michael Wink, and Carmen Magdalena Gurrola-Díaz.
2023. "Combined Gamma Conglutin and Lupanine Treatment Exhibits In Vivo an Enhanced Antidiabetic Effect by Modulating the Liver Gene Expression Profile" Pharmaceuticals 16, no. 1: 117.
https://doi.org/10.3390/ph16010117
APA Style
Guerra-Ávila, P. L., Guzmán, T. J., Domínguez-Rosales, J. A., García-López, P. M., Cervantes-Garduño, A. B., Wink, M., & Gurrola-Díaz, C. M.
(2023). Combined Gamma Conglutin and Lupanine Treatment Exhibits In Vivo an Enhanced Antidiabetic Effect by Modulating the Liver Gene Expression Profile. Pharmaceuticals, 16(1), 117.
https://doi.org/10.3390/ph16010117